article_metadata: Daniel E Pleguezuelo Raquel Díaz-Simón Oscar Cabrera-Marante Antonio Lalueza Estela Paz-Artal Carlos Lumbreras Antonio Serrano Hernández
article_metadata: 10.3389/fimmu.2021.667515
article_metadata: Front Immunol
article_metadata: 2021 Apr 12;12:667515.
article_metadata: anti-cd38 anti-phospholipid daratumumab refractory treatment
article_metadata: CC BY
article_metadata: https://pubmed.ncbi.nlm.nih.gov/33912194/
article_metadata: Antibodies, Antiphospholipid / blood Antibodies, Monoclonal / therapeutic use Antiphospholipid Syndrome / drug therapy Immunity, Humoral / drug effects Immunologic Factors / therapeutic use Plasma Cells / drug effects Venous Thromboembolism / prevention & control
article_metadata: Antibodies, Antiphospholipid / blood Antibodies, Monoclonal / therapeutic use Antiphospholipid Syndrome / drug therapy Immunity, Humoral / drug effects Immunologic Factors / therapeutic use Plasma Cells / drug effects Venous Thromboembolism / prevention & control Case Reports Research Support, Non-U.S. Gov't Anticoagulants / therapeutic use Antiphospholipid Syndrome / blood Antiphospholipid Syndrome / diagnosis Antiphospholipid Syndrome / immunology Biomarkers / blood Female Humans Off-Label Use Plasma Cells / immunology Plasma Cells / metabolism Recurrence Treatment Outcome Venous Thromboembolism / blood Venous Thromboembolism / diagnosis Venous Thromboembolism / immunology Young Adult Antibodies, Antiphospholipid Antibodies, Monoclonal Anticoagulants Biomarkers Immunologic Factors daratumumab
article_metadata: PMC8072150
article_metadata: 33912194
article_metadata: Case Report: Resetting the Humoral Immune Response by Targeting Plasma Cells With Daratumumab in Anti-Phospholipid Syndrome
article_metadata: 2021